*Canadian HCPs only*
Tuesday, Mar 16, 2021
2:00 – 3:00 PM Eastern (11:00 AM Pacific)
Neurology teams (physicians, PAs, NPs, nurses, and pharmacists) providing care for patients with MS
Advances in therapeutics have delivered a multitude of treatment options for multiple sclerosis (MS), including multiple S1P-based disease-modifying therapies (DMTs). Tune into this webcast to hear as Virginia A Devonshire, MD and her esteemed colleagues share their perspectives on the latest advances in MS treatment.
- Key safety and efficacy data on current and emerging MS therapies
- A deep dive into the S1P modulators—their mechanism of action and differentiating characteristics, as well as emerging clinical evidence
- Practical strategies to incorporate the latest evidence into clinical practice and make patient-centered treatment decisions
Accompanying this activity are two clinical practice aids that provide evidence-based guidance on necessary laboratory evaluations needed before initiating or switching DMTs, as well as a guide for evaluating treatment response and recognizing when a switch in therapy may be appropriate.
- Differentiate current and emerging disease-modifying therapies (DMTs) for multiple sclerosis (MS), including S1P modulators, based on their mechanism of action
- Evaluate new clinical trial data on the efficacy and safety of current and emerging DMTs
- Apply the latest evidence to patient-centered treatment decision-making to optimize quality of life and outcomes for individuals with MS
- Deciphering New Mechanisms of Action in MS
- Updated Evidence for the Efficacy and Safety of New and Emerging MS Treatments
- Applications to Practice: Translating New Evidence to Clinical Decision-Making in MS
Virginia A Devonshire, MD
Associate Clinical Professor, Division of Neurology
Fellowship Director, UBC Hospital Multiple Sclerosis Clinic
University of British Columbia
Sarah A Morrow, MD, MS, FRCPC, FAAN
Director, London Multiple Sclerosis Clinic
Research Chair, Multiple Sclerosis
London Health Sciences Centre, University Hospital
University of Western Ontario
E Ann Yeh, MA, MD, FRCPC, Dip ABPN
Professor of Pediatrics (Neurology)
Director, Pediatric Multiple Sclerosis and Demyelinating Disorders Program
University of Toronto
Senior Associate Scientist, Division of Neuroscience and Mental Health
Staff Physician, Division of Neurology
The Hospital for Sick Children (SickKids Research Institute)
Abimbola Farinde, PhD, PharmD
Professor of Health Care Administration
Columbia Southern University College of Business
Orange Beach, AL
Mark A Rubin, MD
Fort Lauderdale, FL
Michele B Kaufman, PharmD, BCGP
New York Presbyterian Hospital – Lower Manhattan
New York, NY
Joint Accreditation Statement
In support of improving patient care, PRIME® is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Credit Designation Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
For Canadian Physicians:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Physician Assistant Accreditation Statement
PRIME® has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.
Nurse Practitioner Accreditation Statement
PRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 1.0 contact hour (which includes 0 hour of pharmacology).
Pharmacist Accreditation Statement
This Application-based activity has been approved for 1.0 contact hour (0.1 CEUs) by PRIME® for pharmacists. The Universal Activity Number for this activity is JA0007144-0000-21-015-L01-P. Pharmacy CE credits will be submitted electronically to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service ([email protected]).
Nurse Accreditation Statement
Obtaining CE Credit
- Register using the online form
- Complete the pre-registration survey
- Attend the live program in its entirety
- Complete an online evaluation and post-test
- Download and/or print a certificate of completion and/or submit CE credits electronically
Instructions to access CME/CE credit options will be provided at the end of the program.
Method of Participation
This live CME/CE activity requires attendance of the participant during the entire program and completion of learner assessment tools. The learner will then receive instructions on how to download and/or print a certificate of completion and/or submit CE credits electronically.
- Hardware: an Internet-enabled computer, smartphone, tablet, or mobile device with audio capabilities and Internet connectivity
- Software: the installation of software such as GoToWebinar may be required
The following individuals have identified relevant financial relationships with commercial interests to disclose:
- Virginia A Devonshire, MD (Speaker)Advisory Board or Panel – Biogen, Novartis, roche, sanofi-genzyme
Consultant – Biogen, Novartis, roche, sanofi-genzyme
Speakers Bureau or other Promotional Education – Biogen, Novartis, alexion, roche, sanofi-genzyme
- E Ann Yeh, MA, MD, FRCPC, Dip ABPN (Moderator)Advisory Board or Panel – Alexion, Biogen, Hoffman-Laroche
Grants / Research Support – Biogen
The following individuals have no relevant financial relationships with commercial interests to disclose:
- Sarah A Morrow, MD, MS, FRCPC, FAAN (Speaker)
- Michele B Kaufman, PharmD, BCGP (Reviewer)
- Abimbola Farinde, PhD, PharmD (Planner)
- Mark A Rubin, MD (Planner)
All PRIME staff participating in planning and content development have no relevant financial relationships with commercial interests to disclose.
This activity is provided by PRIME Education. There is no fee to participate. This activity is supported by an educational grant from Bristol-Myers Squibb Canada.
At PRIME, we are committed to ensuring that individuals with disabilities can access all of the content offered by PRIME through our website and other properties. If you are having trouble accessing primeinc.org, please email [email protected] for assistance. Please put “ADA Inquiry” in the subject line of your email.